Rawash, Mohamed AMohamed, Ayman SaberEl-Zayat, Emad M2021-10-172021-10-172021-10https://doi.org/10.2174/1574888X16666211011124154https://cutt.ly/zRsYT43Background: Adipose mesenchymal stem cells (AMSCs) are a type of stem cell employed to repair damaged organs. This study aimed to see how effective AMSCs are at treating gentamycin-induced hepatorenal damage in rats. Methods: 18 male Wister rats were assigned into three groups; control, Gentamycin (GM), and GM+AMSCs. GM induced hepatorenal toxicity through daily injection (100 mg/kg, i.p.) for eight days. On day 9, AMSC (106 cells/ml/rat) was injected intravenously. Results: Creatinine, urea, uric acid, AST, ALP, ALT, TNF-, and MDA levels decreased, whereas IL-10, GSH, and CAT levels increased, indicating the therapeutic potency of intravenous injection AMSCs. Conclusion: The current study demonstrated the simultaneous therapeutic efficacy of adipose mesenchymal stem cells on the liver and kidney in the treatment of Gentamycin-induced hepatotoxicity. These data show that AMSCs could be a feasible therapy option for liver and kidney diseaseen-USAdipose-derived mesenchymal stem cellsGentamycinAminoglycosidesHepatorenal toxicityOxidative stressHistologyInflammationArticlehttps://doi.org/10.2174/1574888X16666211011124154